Search Results

Elorac Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class, proprietary drugs, announced it has amended its current clinical trial evaluating the safety and efficacy of topically applied naloxone hydrochloride lotion, 0.5%, for the treatment of moderate or severe pruritus in patients with the mycosis fungoides or Sézary Syndrome forms of Cutaneous T-cell Lymphoma (CTCL). The original d

Feb. 10, 2020 15:49 UTC Elorac to Present Naloxone Lotion Phase III Study Update at the 4 th World Congress of Cutaneous Lymphomas in Barcelona CHICAGO--( BUSINESS WIRE )-- Elorac, Inc., a biopharmaceutical company focused on developing best-in-class, innovative, proprietary drugs, announced that Scott Phillips, M.D., Sr. V.P. Scientific Affairs will present an update of its ongoing Phase III SPIRIT-2 trial evaluating the safety and efficacy of naloxone lotion for relief of pruritus